This week in therapeutics




Licensing status

Publication and contact information



RNA polymerase I (Pol I)

In vitro studies identified a small molecule that causes the degradation of the RPA194 catalytic subunit of Pol I and could help treat cancer. A small molecule with broad anticancer activity preferentially bound GC-rich ribosomal DNA, inhibited transcription by Pol I and caused degradation of RPA194 in cancer cell lines. In the cell lines, the molecule inhibited ribosomal RNA synthesis, and reduced cell viability was correlated with lower levels of RPA194. Next steps include testing the compound in animal models.
Senhwa Biosciences Inc. has the Pol I inhibitor CX-5461 in
Phase I testing to treat cancer.

SciBX 7(6); doi:10.1038/scibx.2014.171
Published online Feb. 13, 2014

Patented; available for licensing

Peltonen, K. et al. Cancer Cell; published online Jan. 13, 2014;
Contact: Marikki Laiho, University of Helsinki, Helsinki, Finland